PropThink: Tivantinib Will Not Meet Primary Endpoint, Phase III Trial Discontinued

[ACN Newswire] – By Jake KingShares of ArQule (NASDAQ:ARQL) are being crushed in early trading on Tuesday following an announcement that ArQule and partner Daiichi Sankyo (OTC:DSNKY) will be discontinuing a Phase III non … more

View todays social media effects on ARQL

View the latest stocks trending across Twitter. Click to view dashboard